Search
COVID19 Clinical Trials in Longview, TX
A listing of COVID19 clinical trials in Longview, TX actively recruiting patient volunteers.
1 - 2 of 2
Featured Trial
CMV Vaccine Trial For Young Women Ages 16-17
Recruiting
A Cytomegalovirus (CMV) Investigational Vaccine Clinical Trial for Healthy Women Age 16 to 17 years old. Compensation included.
Conditions:
Healthy Volunteers
Healthy
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Paid Vaccine Study For Teens
Recruiting
Vaccine study that aims to protect teens ages 12–17 against Epstein-Barr virus (EBV) and infectious mononucleosis (mono).
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Adult Migraine Study
Recruiting
Migraine study for adults. You may be compensated up to $800 for your time and travel expenses.
Conditions:
Headache
Cluster Headache
Headache Disorders
Post-Traumatic Headache
Migraine
Menstrual Migraine
Classic Migraine
Migraine
With or Without Aura
* Compensation for time may be available
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi & Co. Ltd.
The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of S-217622 when given in addition to standard... Read More
Gender:
All
Ages:
18 years and above
Locations: CHRISTUS Good Shepherd Medical Center (Site 080-031), Longview, Texas +60 locations
Conditions: COVID-19
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
Recruiting
This study is an adaptive Phase III randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of Proxalutamide (GT0918) in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted globally. The study will compare GT0918 plus standard of care (SOC) with the placebo plus SOC. Approximately 762 subjects will be randomized in a 1:1 ratio to either GT0918 plus SOC or placebo plus SOC group.
Gender:
All
Ages:
18 years and above
Locations: Christus Good Shepherd Medical Center, Longview, Texas +37 locations
Conditions: Covid19
1 - 2 of 2